EGFR and non-small cell lung carcinoma: Presently, five EGFR-TKIs (gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib) are approved by the US Food and Drug Administration (FDA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the first-line treatment of patients with metastatic NSCLC harboring EGFR mutations.